Reply to S Ferraro and M Panteghini

Reply to M. Dhanushkodi

In a letter to the editor in response to our recent article in Journal of Global Oncology titled “Outcomes of Saudi Arabian PatientsWith Nasopharyngeal Cancer Treated With Primarily Neoadjuvant ChemotherapyFollowedbyConcurrentChemoradiotherapy,” Dhanushkodi raises some interesting points. The Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma (MAC-NPC) demonstrated improved overall survival...

Reply to M. Dhanushkodi

We thankDhanushkodi sincerely for his questions regarding our study, “Cardiovascular Disease Risk Factors:HowRelevant inAfricanMenwithProstate Cancer Receiving Androgen-Deprivation Therapy?” In our facility, the gonadotropin-releasing hormone agonist used is goserelin. The dose administered is 3.6 mg every 28 days subcutaneously until the prostate-specific antigen (PSA) level is 0 ng/mL. Then t...

M . Hubbard and V . S . Ramachandran Refining the Experimental Lever A Reply to Shanon and Pribram

The commentaries by Shanon (2003) and Pribram (2003) on our original article (Ramachandran & Hubbard, 2001) are stimulating and make a valuable contribution to the knowledge and thinking about synaesthesia, and indeed the mind in general. We were gratified to see the overall level of agreement with our general framework. For example, both of the authors endorse our connection between the percep...

Reply to S. Rastogi et al

Yellow fever vaccine-reply to S. arya

Letters tion centers in Lagos was fully potent, but potency in Osun and Oyo was 016 log 10 to 0.22 log 10 lower than the stipulated level (2). Furthermore, the titer of two vaccine lots that had been frozen after reconstitution from their lyophilized state dropped from the initial 3.15 log 10 to 3.53 log 10 to zero. If the United States were to implement an extended strategy, similar studies of...